C1QTNF6: A Promising Drug Target and Biomarker for Tumor Necrosis Factor-Related Protein 6

Target Name: C1QTNF6

NCBI ID: G114904

C1QTNF6

C1QTNF6: A Promising Drug Target and Biomarker for Tumor Necrosis Factor-Related Protein 6

Introduction

Tumor necrosis factor-related protein 6 (C1QTNF6) is a cytokine that plays a crucial role in the regulation of cellular processes, including inflammation and cell death. The abnormally activated C1QTNF6 has been implicated in various diseases, including cancer. As a result, targeting C1QTNF6 has become an attractive research focus. In this article, we will explore C1QTNF6 as a drug target and biomarker.

C1QTNF6: Structure and Function

C1QTNF6 is a 21-kDa protein that belongs to the interleukin-1 family. It is expressed in various tissues, including the liver, spleen, and peripheral blood mononuclear cells (PBMCs). C1QTNF6 has four isoforms, including isoform 1 (C1QTNF6), isoform 2, isoform 3, and isoform 4. The isoforms differ in their amino acid sequences.

The C1QTNF6 gene has a promoter, an open reading frame and a C-terminal hypervariable region (HVR). The HVR is involved in the formation of the protein structure and functions. The C1QTNF6 protein has a molecular weight of 19.9 kDa and a calculated pI of 4.8.

C1QTNF6 is involved in the regulation of cellular processes, including cell adhesion, migration, and cytokine signaling. It has been shown to play a role in the development and progression of various diseases, including cancer.

Drug Targeting C1QTNF6

Drug targeting C1QTNF6 can be achieved through various strategies, including inhibition of its downstream pathways, modulation of its expression signaling levels, and characterization of its interactions with other proteins.

1. Inhibition of the downstream signaling pathways: C1QTNF6 plays a role in the regulation of cell survival and has been shown to promote the survival of cancer cells. Therefore, inhibiting its downstream signaling pathways, such as the PI3K/Akt signaling pathway, could be an attractive strategy for drug targeting C1QTNF6.

2. Modulation of its expression levels: C1QTNF6 expression levels have been shown to be regulated by various factors, including post-transcriptional regulation, RNA-binding protein (RNA-binding protein) and phosphorylation. Therefore, manipulating its expression levels by either increasing or decreasing its levels could be another potential strategy for drug targeting C1QTNF6.

3. Characterization of its interactions with other proteins: C1QTNF6 has been shown to interact with various proteins, including PD-L1, TIM-3 and NF-kappa-B, etc. Therefore, blocking these interactions by using small molecules or antibodies could be an additional strategy for drug targeting C1QTNF6.

Biomarker C1QTNF6

C1QTNF6 has been shown to have various biological functions, including regulating cell death, promoting cell proliferation, and enhancing the survival of cancer cells. Therefore, C1QTNF6 can be used as a potential biomarker for detecting tumor progression and therapeutic effect.

1. Cancer progression: C1QTNF6 has been shown to be overexpressed in various types of cancer, including lung cancer, liver cancer, breast cancer, etc. Therefore, by detecting the expression level of C1QTNF6, the degree of tumor progression can be assessed.

2. Treatment response: C1QTNF6 has been shown to be a potential biomarker for evaluating the efficacy of anti-cancer drugs. For example, a study found that the expression of

Protein Name: C1q And TNF Related 6

The "C1QTNF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1QTNF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets